home / stock / kros / kros news

KROS News and Press, Keros Therapeutics Inc. From 02/10/23

Stock Information
Company Name: Keros Therapeutics Inc.
Stock Symbol: KROS
Market: NASDAQ
Website: kerostx.com
Menu
KROS KROS Quote KROS Short KROS News KROS Articles KROS Message Board
Get KROS Alerts

News, Short Squeeze, Breakout and More Instantly...
KROS - Keros Therapeutics: Market Rewarding KER-050 Trial Momentum

Summary Data is promising for KROS' KER-050 compound; investors are rewarding the company on its novel hypotheses. We performed a deep dive on its most recent readouts on KER-050. Market generated data is supportive and we see potential future upside targets forming. Net-net, ra...
KROS - Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference

LEXINGTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and ...

KROS - Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition

LEXINGTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and ...

KROS - Keros Therapeutics to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonar...
KROS - Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonar...

KROS - Keros Therapeutics GAAP EPS of -$0.92 beats by $0.31

Keros Therapeutics press release ( NASDAQ: KROS ): Q3 GAAP EPS of -$0.92 beats by $0.31 . Keros’ cash and cash equivalents as of September 30, 2022 was $239.4 million compared to $230.0 million as of December 31, 2021. The company expects that the ...

KROS - Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047

LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonar...
KROS - Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...

KROS - Why Shares of Keros Therapeutics Rose 10.2% This Week

Shares of clinical-stage biopharmaceutical company Keros Therapeutics (NASDAQ: KROS) rose 10.2% this past week, according to data from S&P Global Intelligence . The stock closed at $39.87 last Friday. It opened on Monday at $40.66, then rose to $47.06 on Friday before fallin...

KROS - Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmona...
Previous 10 Next 10